The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Feb. 21, 2017

Filed:

Mar. 31, 2016
Applicant:

Clearside Biomedical, Inc., Alpharetta, GA (US);

Inventors:

Vladimir Zarnitsyn, Atlanta, GA (US);

Samirkumar Patel, Atlanta, GA (US);

Daniel White, Suwanee, GA (US);

Glenn Noronha, Atlanta, GA (US);

Brian Burke, Cary, NC (US);

Jennifer Kissner, Alpharetta, GA (US);

Assignee:

CLEARSIDE BIOMEDICAL, INC., Alpharetta, GA (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 9/00 (2006.01); A61K 9/10 (2006.01); A61K 9/16 (2006.01); A61K 31/573 (2006.01); A61K 31/4439 (2006.01); A61K 39/00 (2006.01); A61K 45/06 (2006.01); A61K 47/12 (2006.01); A61K 47/26 (2006.01); A61K 47/38 (2006.01); A61M 37/00 (2006.01); C07K 16/22 (2006.01);
U.S. Cl.
CPC ...
A61K 31/4439 (2013.01); A61K 9/0019 (2013.01); A61K 9/0048 (2013.01); A61K 9/10 (2013.01); A61K 9/16 (2013.01); A61K 31/573 (2013.01); A61K 45/06 (2013.01); A61K 47/12 (2013.01); A61K 47/26 (2013.01); A61K 47/38 (2013.01); A61M 37/0015 (2013.01); C07K 16/22 (2013.01); A61K 2039/505 (2013.01); A61K 2039/54 (2013.01); A61M 2037/0023 (2013.01); A61M 2037/0061 (2013.01);
Abstract

Methods and devices are provided for targeted non-surgical administration of a drug formulation to the suprachoroidal space (SCS) of the eye of a human subject for the treatment of a posterior ocular disorder or a choroidal malady. In one embodiment, the method comprises inserting a hollow microneedle into the eye at an insertion site and infusing a drug formulation through the inserted microneedle and into the suprachoroidal space of the eye, wherein the infused drug formulation flows within the suprachoroidal space away from the insertion site during the infusion. In one embodiment, the fluid drug formulation comprises drug nanoparticles or microparticles.


Find Patent Forward Citations

Loading…